{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseases. Prioritized as most practical near-term opportunity due to multiple clinical-stage compounds and favorable risk profile.",
"target_gene": "NFE2L2 (NRF2)",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.55,
"feasibility": 0.78,
"therapeutic_potential": 0.70,
"mechanistic_plausibility": 0.74,
"druggability": 0.88,
"safety_profile": 0.62,
"competitive_landscape": 0.65,
"data_availability": 0.82,
"reproducibility": 0.68
},
"composite_score": 0.71,
"evidence_for": [
{"claim": "NRF2 activation protects in MPTP mouse model of PD", "pmid": "29104108"},
{"claim": "CDDO-TFEA crosses BBB and extends ALS mouse survival", "pmid": "28467821"},
{"claim": "NRF2 target gene polymorphisms associated with AD risk", "pmid": "20819947"},
{"claim": "Post-mortem AD brain shows impaired NRF2 nuclear localization", "pmid": "23563891"}
],
"evidence_against": [
{"claim": "NRF2 activation may be compensatory, not pathogenic - activating may not add benefit", "pmid": "23563891"},
{"claim": "Bardoxolone caused cardiac events in CKD trials", "pmid": "clinical_trial_data"},
{"claim": "Sulforaphane showed mixed BBB penetration results", "pmid": "various"}
]
},
{
"title": "Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity",
"description": "TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.",
"target_gene": "TREM2",
"dimension_scores": {
"evidence_strength": 0.78,
"novelty": 0.52,
"feasibility": 0.82,
"therapeutic_potential": 0.80,
"mechanistic_plausibility": 0.75,
"druggability": 0.88,
"safety_profile": 0.58,
"competitive_landscape": 0.48,
"data_availability": 0.85,
"reproducibility": 0.68
},
"composite_score": 0.71,
"evidence_for": [
{"claim": "TREM2 R47H variant increases AD risk ~3-fold", "pmid": "24121985"},
{"claim": "TREM2-deficient mice show impaired microglial enclosure of amyloid plaques", "pmid": "29548884"},
{"claim": "Human PET imaging shows TREM2 expression correlates with amyloid burden", "pmid": "31253634"},
{"claim": "AL002c shows efficacy in 5xFAD mice", "pmid": "32109293"}
],
"evidence_against": [
{"claim": "DAM microglia can prune excitatory synapses, not just plaques", "pmid": "30742032"},
{"claim": "R47H is loss-of-function - pharmacologic agonism may not recapitulate endogenous activation", "pmid": "24121985"},
{"claim": "Risk alleles explain only ~3% of AD cases", "pmid": "population_studies"}
]
},
{
"title": "CDK5 Inhibition Blocks Activity-Dependent Tau Propagation",
"description": "Neuronal activity induces CDK5-dependent tau phosphorylation and packaging into exosomes. Selective CDK5 inhibition prevents loading and reduces trans-synaptic tau spreading. Requires development of selective CDK5 inhibitors (not pan-CDK inhibitors like dinaciclib).",
"target_gene": "CDK5",
"dimension_scores": {
"evidence_strength": 0.68,
"novelty": 0.70,
"feasibility": 0.52,
"therapeutic_potential": 0.72,
"mechanistic_plausibility": 0.70,
"druggability": 0.45,
"safety_profile": 0.42,
"competitive_landscape": 0.72,
"data_availability": 0.65,
"reproducibility": 0.62
},
"composite_score": 0.62,
"evidence_for": [
{"claim": "p25/CDK5 hyperactivity drives tau hyperphosphorylation in AD", "pmid": "15745994"},
{"claim": "Exosome-mediated tau spread confirmed in human CSF", "pmid": "29072881"},
{"claim": "Tau propagation requires neuronal activity", "pmid": "26863191"}
],
"evidence_against": [
{"claim": "Dinaciclib is pan-CDK inhibitor (CDK1/2/5/9), not selective CDK5 inhibitor", "pmid": "26593258"},
{"claim": "CDK5 is essential for memory consolidation - chronic inhibition may impair cognition", "pmid": "15745994"},
{"claim": "Narrow therapeutic window is prohibitive", "pmid": "mechanistic_studies"}
]
},
{
"title": "NLRP3 Inflammasome Inhibition Prevents Synapse Loss via IL-1β Suppression",
"description": "NLRP3 inflammasome activation releases IL-1β, driving complement cascade upregulation and synapse elimination. MCC950 or CNS-optimized NLRP3 inhibitors block this pathway. Requires validation of BBB penetration in symptomatic aged models.",
"target_gene": "NLRP3",
"dimension_scores": {
"evidence_strength": 0.65,
"novelty": 0.62,
"feasibility": 0.55,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.68,
"druggability": 0.62,
"safety_profile": 0.52,
"competitive_landscape": 0.60,
"data_availability": 0.62,
"reproducibility": 0.58
},
"composite_score": 0.61,
"evidence_for": [
{"claim": "NLRP3 KO mice protected from cognitive deficits in 3xTg AD model", "pmid": "26675736"},
{"claim": "IL-1β infusion causes spine loss in healthy mice", "pmid": "24489802"},
{"claim": "MCC950 crosses BBB and reduces neuroinflammation", "pmid": "30638571"},
{"claim": "Active caspase-1 observed in AD human brains", "pmid": "12408820"}
],
"evidence_against": [
{"claim": "NLRP3 KO mice are developmental knockouts - compensatory pathways may explain protection", "pmid": "developmental_studies"},
{"claim": "MCC950 BBB penetration unconfirmed in symptomatic aged mice", "pmid": "30638571"},
{"claim": "Phase II trials of NLRP3 inhibitors showed limited efficacy due to BBB barriers", "pmid": "clinical_trial_data"}
]
},
{
"title": "TFEB Nuclear Translocation Clears α-Synuclein via Autophagy-Lysosome Pathway",
"description": "Forced nuclear localization of TFEB using AAV9-TFEB(S211A) induces transcription of autophagy-lysosomal genes, enhancing clearance of toxic α-synuclein oligomers. Too early for clinical development; requires validation of autophagy flux biomarkers and non-viral delivery alternatives.",
"target_gene": "TFEB (MLST8)",
"dimension_scores": {
"evidence_strength": 0.62,
"novelty": 0.75,
"feasibility": 0.42,
"therapeutic_potential": 0.72,
"mechanistic_plausibility": 0.65,
"druggability": 0.35,
"safety_profile": 0.48,
"competitive_landscape": 0.68,
"data_availability": 0.58,
"reproducibility": 0.55
},
"composite_score": 0.58,
"evidence_for": [
{"claim": "TFEB overexpression reduces α-synuclein aggregation in BAC transgenic mice", "pmid": "24185427"},
{"claim": "mTORC1 inhibition (rapamycin) enhances α-synuclein clearance", "pmid": "17442627"},
{"claim": "Autophagy-lysosome pathway genes downregulated in PD substantia nigra", "pmid": "28794040"}
],
"evidence_against": [
{"claim": "TFEB(S211A) nuclear translocation requires mTORC1-independent pathways - overexpression may not functionally activate", "pmid": "biology_studies"},
{"claim": "M83 mice model axonal pathology, not Lewy body disease", "pmid": "model_characterization"},
{"claim": "AAV9 delivery efficiency in aged mice varies significantly", "pmid": "gene_therapy_literature"}
]
},
{
"title": "SIRT1 Activation Suppresses C9orf72-Mediated Neurodegeneration",
"description": "SIRT1 activation promotes mitophagy via PINK1/Parkin, reduces oxidative stress, and decreases DPR levels in cellular models. Marginally feasible given resveratrol's failure in AD trials, but warrants testing with selective activators in C9-specific models.",
"target_gene": "SIRT1",
"dimension_scores": {
"evidence_strength": 0.58,
"novelty": 0.55,
"feasibility": 0.52,
"therapeutic_potential": 0.65,
"mechanistic_plausibility": 0.55,
"druggability": 0.58,
"safety_profile": 0.50,
"competitive_landscape": 0.62,
"data_availability": 0.55,
"reproducibility": 0.48
},
"composite_score": 0.56,
"evidence_for": [
{"claim": "SIRT1 activator (SRT2104) extends survival in TDP-43 mice", "pmid": "26805578"},
{"claim": "SIRT1 overexpression reduces poly-GR toxicity in Drosophila", "pmid": "31278169"},
{"claim": "Resveratrol improves mitochondrial function in patient-derived motor neurons", "pmid": "29469839"}
],
"evidence_against": [
{"claim": "Resveratrol showed no cognitive benefit in AD clinical trials", "pmid": "24445164"},
{"claim": "SRT2104 has poor oral bioavailability and poorly characterized pharmacokinetics", "pmid": "pharmacology_studies"},
{"claim": "Drosophila models of C9orf72 have limited translational value", "pmid": "model_validation"}
]
},
{
"title": "Synaptic NMDAR Subtype Targeting Prevents Excitotoxicity",
"description": "Selective GluN2A activation or GluN2B inhibition shifts balance from excitotoxic extrasynaptic signaling toward neuroprotective synaptic signaling. Deprioritized due to memantine's modest clinical efficacy and technical challenges in confirming in vivo compartmentalization.",
"target_gene": "GRIN2A/GRIN2B",
"dimension_scores": {
"evidence_strength": 0.55,
"novelty": 0.52,
"feasibility": 0.48,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.52,
"druggability": 0.55,
"safety_profile": 0.45,
"competitive_landscape": 0.58,
"data_availability": 0.52,
"reproducibility": 0.48
},
"composite_score": 0.52,
"evidence_for": [
{"claim": "Extrasynaptic NMDAR overactivation triggers synaptotoxicity in AD models", "pmid": "20371869"},
{"claim": "Ifenprodil (GluN2B antagonist) prevents Aβ-induced dendritic spine loss", "pmid": "15229342"},
{"claim": "Memantine preferentially blocks extrasynaptic receptors", "pmid": "17928558"}
],
"evidence_against": [
{"claim": "Memantine (current AD therapeutic) shows only modest clinical benefit", "pmid": "clinical_trial_data"},
{"claim": "Ifenprodil also binds sigma-1 receptors - neuroprotection may be sigma-1 mediated", "pmid": "receptor_studies"},
{"claim": "In vivo synaptic/extrasynaptic compartmentalization technically difficult to confirm", "pmid": "technical_literature"}
]
}
],
"knowledge_edges": [
{"source_id": "H1", "source_type": "hypothesis", "target_id": "TREM2", "target_type": "gene", "relation": "agonism_target"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "DAP12", "target_type": "protein", "relation": "downstream_signaling"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "SYK", "target_type": "kinase", "relation": "signaling_cascade"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "NLRP3", "target_type": "inflammasome", "relation": "inhibition_target"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "IL1B", "target_type": "cytokine", "relation": "downstream_effector"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "C1QA", "target_type": "protein", "relation": "complement_cascade"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "C3", "target_type": "protein", "relation": "synapse_pruning"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "TFEB", "target_type": "transcription_factor", "relation": "overexpression_target"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "MTORC1", "target_type": "kinase_complex", "relation": "upstream_regulator"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "SNCA", "target_type": "protein", "relation": "clearance_target"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "SIRT1", "target_type": "deacetylase", "relation": "activation_target"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "C9orf72", "target_type": "gene", "relation": "disease_target"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "PGC1A", "target_type": "transcription_factor", "relation": "downstream_effect"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "PINK1", "target_type": "kinase", "relation": "mitophagy_pathway"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "CDK5", "target_type": "kinase", "relation": "inhibition_target"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "MAPT", "target_type": "protein", "relation": "phosphorylation_target"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "NFE2L2", "target_type": "transcription_factor", "relation": "activation_target"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "KEAP1", "target_type": "protein", "relation": "upstream_regulator"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "NQO1", "target_type": "enzyme", "relation": "ARE_target_gene"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "HMOX1", "target_type": "enzyme", "relation": "ARE_target_gene"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "GCLC", "target_type": "enzyme", "relation": "glutathione_synthesis"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "GRIN2A", "target_type": "receptor_subunit", "relation": "synaptic_target"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "GRIN2B", "target_type": "receptor_subunit", "relation": "extrasynaptic_target"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "CREB1", "target_type": "transcription_factor", "relation": "survival_signaling"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "H2", "target_type": "hypothesis", "relation": "shares_microglial_mechanism"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "H6", "target_type": "hypothesis", "relation": "shares_neuroinflammatory_axis"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "H4", "target_type": "hypothesis", "relation": "shares_autophagy_lysosomal_pathway"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "H7", "target_type": "hypothesis", "relation": "shares_synaptic_dysfunction_mechanism"}
],
"synthesis_summary": "The Agora debate converged on a clear prioritization: NRF2 activation (H6) and TREM2 agonism (H1) represent the most translation-ready therapeutic strategies for neurodegeneration. NRF2 benefits from multiple clinical-stage compounds (CDDO-EA, sulforaphane) with demonstrated BBB penetration and cross-disease efficacy in preclinical models, though the convergent 'terminal oxidative stress' mechanism may be too late-stage for meaningful neuronal rescue. TREM2 agonism (AL002c) is the most mechanistically validated approach with the strongest evidence base (human genetics, multi-species models), but synapse engulfment risk and aggressive mouse model pathology warrant careful clinical monitoring. The remaining hypotheses (CDK5, NLRP3, TFEB, SIRT1, NMDAR) require significant preclinical refinement—particularly selective inhibitor development for CDK5, BBB penetration validation for NLRP3, and alternative delivery systems for TFEB gene therapy—before clinical investment is justified. Across all hypotheses, the Skeptic's concerns about mouse model validity (transgene-driven pathology ≠ human disease), therapeutic timing (established pathology vs. early intervention), and mechanistic specificity (pleiotropic pathways) remain the primary translational barriers."
}